Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Diagnos ( (TSE:ADK) ) has provided an announcement.
Diagnos Inc. has announced an amendment to the terms of its unsecured convertible debentures, extending the maturity date from March 1, 2025, to March 1, 2026, and increasing the interest rate from 8% to 10% for the extended period. This amendment is subject to acceptance by the TSX Venture Exchange and aims to adjust financial terms to better align with market conditions, potentially impacting investor relations and financial strategy.
More about Diagnos
DIAGNOS is a publicly-traded Canadian corporation specializing in the development of software tools for the early detection of critical health issues using Artificial Intelligence.
YTD Price Performance: 13.33%
Average Trading Volume: 220,964
Technical Sentiment Consensus Rating: Hold
Current Market Cap: C$34.37M
See more data about ADK stock on TipRanks’ Stock Analysis page.